Related Experiment Video

Updated: Aug 18, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

484

The Dual Role of PDCD10 in Cancers: A Promising Therapeutic Target

Jingdian Liu1, Kai Zhao1, Sisi Wu1

  • 1Department of Neurosurgery, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Cancers
|December 11, 2022
PubMed

Insights

Programmed cell death 10 (PDCD10) is an adaptor protein involved in many cell functions. Aberrant PDCD10 expression is common in cancers, where it plays a dual role in tumor progression.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Programmed cell death 10 (PDCD10) was initially identified as a protein linked to apoptosis.
  • Emerging evidence reveals PDCD10 functions as a crucial adaptor protein in diverse cellular processes.
  • Aberrant PDCD10 expression and mutations are frequently observed in various pathological conditions, particularly cancers.

Purpose of the Study:

  • To review the multifaceted roles of PDCD10 in cancer development and progression.
  • To elucidate the dual functions of PDCD10, encompassing both pro- and anti-tumor effects.
  • To explore the cellular functions and molecular mechanisms underlying PDCD10's involvement in oncogenesis.

Main Methods:

  • Literature review of recent studies on PDCD10.
  • Analysis of PDCD10's interactions with various molecular partners.
  • Examination of PDCD10's role in different cancer types and cellular contexts.

Main Results:

  • PDCD10 participates in cell survival, migration, differentiation, and development.
  • PDCD10 exhibits context-dependent dual roles in cancer, influencing tumor growth and suppression.
  • Cellular interactors and tissue specificity modulate PDCD10's oncogenic or tumor-suppressive functions.

Conclusions:

  • PDCD10's complex functions extend beyond apoptosis, highlighting its significance as an adaptor protein.
  • Understanding PDCD10's dual role is critical for developing targeted cancer therapies.
  • PDCD10 represents a promising, yet complex, target for future clinical applications in oncology.
Keywords:
PDCD10apoptosiscancersmetastasistumor microenvironment

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

884

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K